Predicting disease course for better relapsing polychondritis care
Treatments studied
Part of Bones, joints & muscles, Heart & circulation, Skin clinical trials.
This trial tests a new approach to treating relapsing polychondritis, a rare autoimmune condition that causes inflammation in cartilage like the ears, nose, and airways. It aims to see if a more tailored treatment can help control symptoms while reducing prednisone use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a diagnosis of relapsing polychondritis (an autoimmune condition causing inflammation in cartilage and tissues) based on standard criteria.
- You must have mild to moderate active disease within the last 60 days, needing a prednisone dose increase to 15-60 mg per day.
- You must have at least one of these active symptoms: ear, nose, eye, joint, or airway inflammation.
- You must agree to use effective birth control if you or your partner can have children.
- You cannot have certain severe complications, recent use of specific biologics, active infections, or other autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people who have been diagnosed with relapsing polychondritis over time. It aims to better understand the condition and how it progresses, which may help future care.
This trial tests whether upadacitinib, an oral medication, is safe and effective for people with relapsing polychondritis that hasn't improved enough with standard treatments. It aims to reduce inflammation and control symptoms.
This study is following people who have been recently diagnosed with polymyalgia rheumatica (a condition causing pain and stiffness in the shoulders and hips) and are starting corticosteroid treatment. The goal is to understand the condition's typical course and outcomes over time.
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
This study compares different treatment strategies for people with rheumatoid arthritis who also have interstitial lung disease (a type of lung scarring). It aims to find the best way to manage both conditions and potentially slow lung damage.
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
Hear when a new Relapsing Polychondritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.